COVID-19: The CIDRAP Viewpoint Part 6: Ensuring a Resilient US Prescription Drug Supply [open pdf - 0B]
From the Document: "An ongoing crisis plagues US healthcare, limits reliable access to critical drugs, and results in serious consequences for patients who need these drugs. Over the past few years, the United States has had more than 250 drug shortages at any point,1 many for critical medications, including both acute drugs for treating emergency situations and chronic drugs for managing serious long-term conditions. And shortages remain a perennial problem. Even though drug shortages have been recognized and tracked in the United States since 2001, the situation has not significantly improved in more than two decades.[...] Emergence of the COVID-19 [coronavirus disease 2019] pandemic in early 2020 has severely stressed the US drug supply chain. COVID-19 has jolted the global pharmaceutical market at all levels and production points. The supply side has been disrupted by production factory closures, shipping delays or shutdowns, and trade limitations or export bans. The demand side has seen dramatically increased need for COVID-19 therapies worldwide."
2020 Regents of the University of Minnesota
Center for Infectious Disease Research & Policy (CIDRAP): https://www.cidrap.umn.edu/